Some investors asked questions on the investor interaction platform: Geli pharmaceutical has announced to expand the production capacity of ritonavir oral tablets (100 mg) and announced the R & D pipeline of anti covid-19 virus oral drugs. The company has the only ritonavir oral tablets approved for listing through bioequivalence research in China. Will ritonavir intermediate of senxuan pharmaceutical, a subsidiary of the company, be supplied to Geli pharmaceutical to help fight the global epidemic?
Jinghua Pharmaceutical Group Co.Ltd(002349) (002349. SZ) said on the investor interaction platform on January 11 that the company has no business dealings with geley pharmaceutical at present.
(source: Daily Economic News)
